Compounds > sb 202190
Page last updated: 2024-11-04

sb 202190 and Spinal Diseases

sb 202190 has been researched along with Spinal Diseases in 2 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Spinal Diseases: Diseases involving the SPINE.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Studer, RK2
Aboka, AM1
Gilbertson, LG2
Georgescu, H2
Sowa, G2
Vo, N2
Kang, JD2

Other Studies

2 other studies available for sb 202190 and Spinal Diseases

ArticleYear
p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration.
    Spine, 2007, Dec-01, Volume: 32, Issue:25

    Topics: Adult; Alginates; Cell Culture Techniques; Cells, Cultured; Culture Media, Conditioned; Dinoprostone

2007
p38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2008, Volume: 26, Issue:7

    Topics: Animals; Cells, Cultured; Cytokines; Dinoprostone; Disease Models, Animal; Gene Expression; Imidazol

2008